List of Figures
Figure 1: Innovation Trends in Product Approvals, 1987–2013 7
Figure 2: Sales Performance of First-in-Class and Non-First-in-Class Products Post Marketing Approval, 2006–2013 8
Figure 3: Relative Survival Rates for the Top 20 Cancers by Site, 2014 24
Figure 4: Molecule Types and Molecular Targets of Marketed Products for Oncology, 2017 33
Figure 5: Molecule Types and Molecular Targets of Marketed Products within Cancer Immunotherapies, 2017 34
Figure 6: Summary of Five-Year Survival Rate, Incidence and Mortality by Site, 2012 35
Figure 7: Pipeline Products by Therapy Area, 2017 36
Figure 8: Cancer Immunotherapies Pipeline Products by Stage of Development and Molecule Type, 2017 37
Figure 9: Cancer Immunotherapies Pipeline Products by Stage of Development and Molecular Target, 2017 39
Figure 10: Molecular Target Category Comparison, Pipeline and Marketed Products, 2017 40
Figure 11: Summary of Incidence, Mortality, Mortality Rates and Cancer Immunotherapies Pipeline Activity by Tumor Site, 2015–2017 40
Figure 12: Comparison of First-in-Class to Established Products in the Cancer Immunotherapies Pipeline by Tumor Site, 2017 42
Figure 13: Overview of First-In-Class Cancer Immunotherapies Products, 2017 43
Figure 14: Percentage Distribution of First-in-Class to Established Products, Cancer Immunotherapies Pipeline, 2017 44
Figure 15: Molecular Target Category Comparison, Pipeline First-In-Class and Established Molecular Targets, 2017 45
Figure 16: Cancer Immunotherapies, Ratio of First-in-Class Pipeline Targets to First-in-Class Pipeline Products 46
Figure 17: Cancer Immunotherapies, Global, Pipeline Products, 2017, Part 1 47
Figure 18: Cancer Immunotherapies, Global, Pipeline Products, 2017, Part 2 48
Figure 19: Cancer Immunotherapies, Global, Pipeline Products, 2017, Part 3 49
Figure 20: Cancer Immunotherapies, Global, Pipeline Products, 2017, Part 4 50
Figure 21: Cancer Immunotherapies, Global, Pipeline Products, 2017, Part 5 51
Figure 22: Cancer Immunotherapies, Global, Pipeline Products, 2017, Part 6 52
Figure 23: Cancer Immunotherapies, Global, Pipeline Products, 2017, Part 7 53
Figure 24: Cancer Immunotherapies, Global, Pipeline Products, 2017, Part 8 54
Figure 25: Cancer Immunotherapies, Global, Pipeline Products, 2017, Part 9 55
Figure 26: Cancer Immunotherapies, Global, Pipeline Products, 2017, Part 10 56
Figure 27: Cancer Immunotherapies, Global, Pipeline Products, 2017, Part 11 57
Figure 28: Cancer Immunotherapies, Global, Pipeline Products, 2017, Part 12 58
Figure 29: Cancer Immunotherapies, Global, Pipeline Products, 2017, Part 13 59
Figure 30: Cancer Immunotherapies, Global, Pipeline Products, 2017, Part 14 60
Figure 31: Cancer Immunotherapies, Global, Pipeline Products, 2017, Part 15 61
Figure 32: Cancer Immunotherapies, Global, Pipeline Products, 2017, Part 16 62
Figure 33: Cancer Immunotherapies, Global, Pipeline Products, 2017, Part 17 63
Figure 34: Cancer Immunotherapies, Global, Pipeline Products, 2017, Part 18 64
Figure 35: Cancer Immunotherapies, Global, Pipeline Products, 2017, Part 19 65
Figure 36: Cancer Immunotherapies, Global, Pipeline Products, 2017, Part 20 66
Figure 37: Cancer Immunotherapies, Global, Pipeline Products, 2017, Part 21 67
Figure 38: Cancer Immunotherapies, Global, Pipeline Products, 2017, Part 22 68
Figure 39: Cancer Immunotherapies, Global, Pipeline Products, 2017, Part 23 69
Figure 40: Cancer Immunotherapies, Global, Pipeline Products, 2017, Part 24 70
Figure 41: Cancer Immunotherapies, Global, Pipeline Products, 2017, Part 25 71
Figure 42: Cancer Immunotherapies, Global, Pipeline Products, 2017, Part 26 72
Figure 43: Cancer Immunotherapies, Global, Pipeline Products, 2017, Part 27 73
Figure 44: Cancer Immunotherapies, Global, Pipeline Products, 2017, Part 28 74
Figure 45: Cancer Immunotherapies, Global, Pipeline Products, 2017, Part 29 75
Figure 46: Cancer Immunotherapies, Global, Pipeline Products, 2017, Part 30 76
Figure 47: Cancer Immunotherapies, Global, Pipeline Products, 2017, Part 31 77
Figure 48: Cancer Immunotherapies, Global, Pipeline Products, 2017, Part 32 78
Figure 49: Cancer Immunotherapies, Global, First-in-Class Molecular Target Analysis Matrix, 2017, Part 1 80
Figure 50: Cancer Immunotherapies, Global, First-in-Class Molecular Target Analysis Matrix, 2017, Part 2 81
Figure 51: Cancer Immunotherapies, Global, First-in-Class Molecular Target Analysis Matrix, 2017, Part 3 82
Figure 52: Cancer Immunotherapies, Global, First-in-Class Molecular Target Analysis Matrix, 2017, Part 4 83
Figure 53: Pipeline Programs Targeting XXX 85
Figure 54: Pipeline Programs Targeting XXX 86
Figure 55: Pipeline Programs Targeting XXX 88
Figure 56: Pipeline Programs Targeting XXX 89
Figure 57: Pipeline Programs Targeting XXX 91
Figure 58: Pipeline Programs Targeting XXX 91
Figure 59: Pipeline Programs Targeting XXX 92
Figure 60: Pipeline Programs Targeting XXX 93
Figure 61: Pipeline Programs XXX 95
Figure 62: Pipeline Programs Targeting XXX 96
Figure 63: Pipeline Programs Targeting XXX 97
Figure 64: Cancer Immunotherapies, Global, Licensing Deals by Region and Value, 2006–Q1 2017 99
Figure 65: Cancer Immunotherapies, Global, Licensing Deals by Stage and Value, 2006–Q1 2017 100
Figure 66: Cancer Immunotherapies, Global, Licensing Deals by Molecule Type, 2006–Q1 2017 101
Figure 67: Cancer Immunotherapies, Global, Licensing Deals by Molecular Target, 2006–Q1 2017 102
Figure 68: Cancer Immunotherapies, Licensing Deals with Disclosed Values, 2006–Q1 2017, Part 1 103
Figure 69: Cancer Immunotherapies, Licensing Deals with Disclosed Values, 2006–Q1 2017, Part 2 104
Figure 70: Cancer Immunotherapies, Licensing Deals with Disclosed Values, 2006–Q1 2017, Part 3 105
Figure 71: Cancer Immunotherapies, Global, Co-development Deals by Region and Value, 2006–Q1 2017 106
Figure 72: Cancer Immunotherapies, Global, Co-development Deals by Stage and Value, 2006–Q1 2017 107
Figure 73: Cancer Immunotherapies, Global, Co-development Deals by Molecule Type, 2006–Q1 2017 107
Figure 74: Cancer Immunotherapies, Global, Co-development Deals by Molecular Target, 2006–Q1 2017 108
Figure 75: Cancer Immunotherapies, Global, Co-development Deals with Disclosed Values, 2006–Q1 2017 109
Figure 76: Cancer Immunotherapies, Global, First-in-Class Products with No Prior Deal Involvement, 2006–Q1 2017, Part 1 110
Figure 77: Cancer Immunotherapies, Global, First-in-Class Products with No Prior Deal Involvement, 2006–Q1 2017, Part 2 111
Figure 78: Cancer Immunotherapies, Global, First-in-Class Products with No Prior Deal Involvement, 2006–Q1 2017, Part 3 112
Figure 79: Cancer Immunotherapies, Global, First-in-Class Products with No Prior Deal Involvement, 2006–Q1 2017, Part 4 113
Figure 80: Cancer Immunotherapies, Global, First-in-Class Products with No Prior Deal Involvement, 2006–Q1 2017, Part 5 114
Figure 81: Cancer Immunotherapies, Global, First-in-Class Products with No Prior Deal Involvement, 2006–Q1 2017, Part 6 115
Figure 82: Cancer Immunotherapies, Global, First-in-Class Products with No Prior Deal Involvement, 2006–Q1 2017, Part 7 116
Figure 83: Cancer Immunotherapies, Global, First-in-Class Products with No Prior Deal Involvement, 2006–Q1 2017, Part 8 117
Figure 84: Cancer Immunotherapies, Global, First-in-Class Products with No Prior Deal Involvement, 2006–Q1 2017, Part 9 118
Figure 85: Cancer Immunotherapies, Global, First-in-Class Products with No Prior Deal Involvement, 2006–Q1 2017, Part 10 119
Figure 86: Cancer Immunotherapies, Global, First-in-Class Products with No Prior Deal Involvement, 2006–Q1 2017, Part 11 120